Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Next Previous
Trial Profile

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depemokimab (Primary) ; Corticosteroids
  • Indications Acute asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SWIFT 1
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 06 Jan 2026 According to GSK media release, results from the SWIFT trials were presented at the 2024 European Respiratory Society International Conference.
  • 06 Jan 2026 According to GSK media release, primary endpoint (Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks) has been met.
  • 06 Jan 2026 According to GSK media release, based on data from SWIFT-1 and 2 and ANCHOR-1 and 2 trials, Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Exdensur (depemokimab) for severe asthma and chronic rhinosinusitis with nasal polyps. It becomes the first and only ultra-long-acting biologic in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top